At Oxis, we develop and commercialize innovative immunotherapies for the treatment of cancer and other unmet medical needs.

OXS-1550 For NON-Hodgkin's Lymphoma

OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate.

View OXS-1550 »

OXS-2175 For Triple-Negative Breast Cancer

OXS-2175 is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer.

View OXS-2175 »

OXS-4235 for Multiple Myeloma

OXS-4235 is a small molecule therapeutic candidate that targets the treatment of multiple myeloma and associated osteolytic lesions.

View OXS-4235 »